» Articles » PMID: 33017725

The PKC Universe Keeps Expanding: From Cancer Initiation to Metastasis

Overview
Journal Adv Biol Regul
Publisher Elsevier
Date 2020 Oct 5
PMID 33017725
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Classical and novel protein kinase C (PKC) isozymes (c/nPKCs), members of the PKC family that become activated by the lipid second messenger diacylglycerol (DAG) and phorbol esters, exert a myriad of cellular effects that impact proliferative and motile cellular responses. While c/nPKCs have been indisputably associated with tumor promotion, their roles exceed by far their sole involvement as promoter kinases. Indeed, this original dogma has been subsequently redefined by the introduction of several new concepts: the identification of tumor suppressing roles for c/nPKCs, and their participation in early and late stages of carcinogenesis. This review dives deep into the intricate roles of c/nPKCs in cancer initiation as well as in the different stages of the metastatic cascade, with great emphasis in their involvement in cancer cell motility via regulation of small Rho GTPases, the production of extracellular matrix (ECM)-degrading proteases, and the epithelial-to-mesenchymal transition (EMT) program required for the acquisition of highly invasive traits. Here, we highlight functional interplays between either PKCα or PKCε and mesenchymal features that may ultimately contribute to anticancer drug resistance in cellular and animal models. We also introduce the novel hypothesis that c/nPKCs may be implicated in the control of immune evasion through the regulation of immune checkpoint protein expression. In summary, dissecting the colossal complexity of c/nPKC signaling in the wide spectrum of cancer progression may bring new opportunities for the development of meaningful tools aiding for cancer prognosis and therapy.

Citing Articles

PKCα Activation via the Thyroid Hormone Membrane Receptor Is Key to Thyroid Cancer Growth.

Campos Haedo M, Diaz Albuja J, Camarero S, Cayrol F, Sterle H, Debernardi M Int J Mol Sci. 2024; 25(22).

PMID: 39596225 PMC: 11594262. DOI: 10.3390/ijms252212158.


Hunting the Cell Cycle .

Norris V Life (Basel). 2024; 14(10).

PMID: 39459514 PMC: 11509034. DOI: 10.3390/life14101213.


Special Issue: "Molecular Dynamics Simulations and Structural Analysis of Protein Domains".

de Brevern A Int J Mol Sci. 2024; 25(19).

PMID: 39409122 PMC: 11477144. DOI: 10.3390/ijms251910793.


Preliminary study on cytotoxicity of selegiline on different cancer cell lines: exploration of the induction of ROS-independent apoptosis in breast cancer cells.

Kumkar P, Chakraborty R, Upadhyay A, Das J, Bala A Med Oncol. 2024; 41(8):204.

PMID: 39033171 DOI: 10.1007/s12032-024-02451-0.


An Update on Protein Kinases as Therapeutic Targets-Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases.

Silnitsky S, Rubin S, Zerihun M, Qvit N Int J Mol Sci. 2023; 24(24).

PMID: 38139428 PMC: 10743896. DOI: 10.3390/ijms242417600.